222 related articles for article (PubMed ID: 28467293)
41. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
Stohl W; Schwarting A; Okada M; Scheinberg M; Doria A; Hammer AE; Kleoudis C; Groark J; Bass D; Fox NL; Roth D; Gordon D
Arthritis Rheumatol; 2017 May; 69(5):1016-1027. PubMed ID: 28118533
[TBL] [Abstract][Full Text] [Related]
42. Pneumococcal vaccination in patients with systemic lupus erythematosus: A multicenter placebo-controlled randomized double-blind study.
Grabar S; Groh M; Bahuaud M; Le Guern V; Costedoat-Chalumeau N; Mathian A; Hanslik T; Guillevin L; Batteux F; Launay O;
Vaccine; 2017 Sep; 35(37):4877-4885. PubMed ID: 28784280
[TBL] [Abstract][Full Text] [Related]
43. Belimumab. No tangible efficacy but a risk of immunosuppression.
Prescrire Int; 2013 Jun; 22(139):149. PubMed ID: 23866349
[TBL] [Abstract][Full Text] [Related]
44. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
Roth DA; Thompson A; Tang Y; Hammer AE; Molta CT; Gordon D
Lupus; 2016 Apr; 25(4):346-54. PubMed ID: 26385220
[TBL] [Abstract][Full Text] [Related]
45. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study.
Touma Z; Sayani A; Pineau CA; Fortin I; Matsos M; Ecker GA; Chow A; Iczkovitz S
Rheumatol Int; 2017 Jun; 37(6):865-873. PubMed ID: 28280970
[TBL] [Abstract][Full Text] [Related]
46. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
Harvey PR; Gordon C
BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
[TBL] [Abstract][Full Text] [Related]
47. Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn's disease.
Kantsø B; Halkjær SI; Thomsen OØ; Belard E; Gottschalck IB; Jørgensen CS; Krogfelt KA; Slotved HC; Ingels H; Petersen AM
Vaccine; 2015 Oct; 33(41):5464-5469. PubMed ID: 26275480
[TBL] [Abstract][Full Text] [Related]
48. Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment.
Strand V; Berry P; Lin X; Asukai Y; Punwaney R; Ramachandran S
Arthritis Care Res (Hoboken); 2019 Jun; 71(6):829-838. PubMed ID: 30320964
[TBL] [Abstract][Full Text] [Related]
49. The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis.
Wilkinson C; Henderson RB; Jones-Leone AR; Flint SM; Lennon M; Levy RA; Ji B; Bass DL; Roth D
Arthritis Res Ther; 2020 May; 22(1):102. PubMed ID: 32366280
[TBL] [Abstract][Full Text] [Related]
50. Belimumab for systemic lupus erythematosus: a practice-based view.
Parodis I; Axelsson M; Gunnarsson I
Lupus; 2013 Apr; 22(4):372-80. PubMed ID: 23553780
[TBL] [Abstract][Full Text] [Related]
51. The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study.
Bae SC; Bass DL; Chu M; Curtis P; Dimelow R; Harvey L; Ji B; Kurrasch R; Muzaffar S; Punwaney R; Roth DA; Song YW; Xie W; Zhang F
Arthritis Res Ther; 2022 Feb; 24(1):46. PubMed ID: 35172878
[TBL] [Abstract][Full Text] [Related]
52. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus.
Merrill JT; Ginzler EM; Wallace DJ; McKay JD; Lisse JR; Aranow C; Wellborne FR; Burnette M; Condemi J; Zhong ZJ; Pineda L; Klein J; Freimuth WW;
Arthritis Rheum; 2012 Oct; 64(10):3364-73. PubMed ID: 22674457
[TBL] [Abstract][Full Text] [Related]
53. Immunogenicity of sequential 13-valent conjugated and 23-valent unconjugated pneumococcal vaccines in a population of children with lupus.
Gorelik M; Elizalde A; Wong Williams K; Gonzalez E; Cole JL
Lupus; 2018 Dec; 27(14):2228-2235. PubMed ID: 30380992
[TBL] [Abstract][Full Text] [Related]
54. Comparison of two-dose priming plus 9-month booster with a standard three-dose priming schedule for a ten-valent pneumococcal conjugate vaccine in Nepalese infants: a randomised, controlled, open-label, non-inferiority trial.
Hamaluba M; Kandasamy R; Upreti SR; Subedi GR; Shrestha S; Bhattarai S; Gurung M; Pradhan R; Voysey M; Gurung S; Pradhan S; Thapa AK; Maharjan R; Kiran U; Kerridge SA; Hinds J; van der Klis F; Snape MD; Murdoch DR; Kelly S; Kelly DF; Adhikari N; Thorson S; Pollard AJ
Lancet Infect Dis; 2015 Apr; 15(4):405-14. PubMed ID: 25701560
[TBL] [Abstract][Full Text] [Related]
55. The safety of belimumab for the treatment of systemic lupus erythematosus.
Wise LM; Stohl W
Expert Opin Drug Saf; 2019 Dec; 18(12):1133-1144. PubMed ID: 31657965
[No Abstract] [Full Text] [Related]
56. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting.
Gatto M; Saccon F; Zen M; Regola F; Fredi M; Andreoli L; Tincani A; Urban ML; Emmi G; Ceccarelli F; Conti F; Bortoluzzi A; Govoni M; Tani C; Mosca M; Ubiali T; Gerosa M; Bozzolo E; Canti V; Cardinaletti P; Gabrielli A; Tanti G; Gremese E; De Marchi G; De Vita S; Fasano S; Ciccia F; Pazzola G; Salvarani C; Negrini S; Puppo F; Di Matteo A; De Angelis R; Orsolini G; Rossini M; Faggioli P; Laria A; Piga M; Mathieu A; Scarpato S; Rossi FW; de Paulis A; Brunetta E; Ceribelli A; Selmi C; Prete M; Racanelli V; Vacca A; Bartoloni E; Gerli R; Larosa M; Iaccarino L; Doria A
Arthritis Rheumatol; 2020 Aug; 72(8):1314-1324. PubMed ID: 32275125
[TBL] [Abstract][Full Text] [Related]
57. Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy: a post hoc longitudinal study.
Urowitz MB; Ohsfeldt RL; Wielage RC; Dever JJ; Zakerifar M; Asukai Y; Ramachandran S; Joshi AV
Lupus Sci Med; 2020 Oct; 7(1):. PubMed ID: 33051264
[TBL] [Abstract][Full Text] [Related]
58. Immunogenicity, safety and tolerability of anti-pneumococcal vaccination in systemic lupus erythematosus patients: An evidence-informed and PRISMA compliant systematic review and meta-analysis.
Adawi M; Bragazzi NL; McGonagle D; Watad S; Mahroum N; Damiani G; Conic R; Bridgewood C; Mahagna H; Giacomelli L; Eggenhöffner R; Mahamid M; Pigatto PDM; Amital H; Watad A
Autoimmun Rev; 2019 Jan; 18(1):73-92. PubMed ID: 30408581
[TBL] [Abstract][Full Text] [Related]
59. Effect of belimumab in patients with systemic lupus erythematosus treated with low dose or no corticosteroids.
Lee YJ; Ahn SM; Hong S; Oh JS; Lee CK; Yoo B; Kim YG
Korean J Intern Med; 2024 Mar; 39(2):338-346. PubMed ID: 38031366
[TBL] [Abstract][Full Text] [Related]
60. Patient- and Physician-reported Satisfaction With Systemic Lupus Erythematosus Treatment in US Clinical Practice.
Pascoe K; Lobosco S; Bell D; Hoskin B; Chang DJ; Pobiner B; Ramachandran S
Clin Ther; 2017 Sep; 39(9):1811-1826. PubMed ID: 28803702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
